Otsuka Pharmaceuticals and Click Therapeutics have introduced Rejoyn, an innovative smartphone app cleared by the FDA for patients with major depressive disorder (MDD). Designed as an adjunct to traditional care, Rejoyn aims to improve cognitive control over emotions for patients aged 22 and older who are currently on antidepressant medications. This digital therapeutic combines cognitive emotional training with therapeutic exercises in a six-week program, providing a novel approach to enhancing brain function and emotional regulation.
Rejoyn’s development is rooted in neuromodulatory principles, offering personalized brain-training exercises intended to strengthen neural connections in areas affected by depression. According to Dr. Brian Iacoviello of the Icahn School of Medicine at Mount Sinai, this method can foster more balanced brain activity, potentially alleviating depression symptoms.
This breakthrough is part of a broader trend in digital therapeutics, reflecting Otsuka and Click Therapeutics’ commitment to advancing mental health treatment. Their partnership began with the Mirai study, exploring the effectiveness of digital interventions for adults with MDD. With Rejoyn set to launch in the latter half of 2024, this collaboration underscores a significant step forward in harnessing technology to address the complexities of depression, promising a new horizon in mental health care.
So…:
What other opportunities do you see for using technological solutions within the healthcare industry?
Source & Picture: